MilliporeSigma Opens US$ 65 Million CDMO Facility to Address Demand for Critical Cancer Therapies

Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs) MilliporeSigma now one of industry’s largest manufacturers of these components globally Builds on company’s 30 years’ CDMO experience with multi-step, complex, and highly potent compounds…